Longevity Health Holdings, Inc. and True Health Inc.’s THPlasma division finalize an all-stock merger agreement to unite plasma-derived growth factor platforms with a fast-growing plasma collection network. By leveraging THPlasma’s profitable centers and Longevity’s aging-focused R&D, the combined company aims to address U.S. plasma shortfalls and accelerate healthy aging therapies.
Key points
All-stock merger values THPlasma at $59M plus $20M earnout, set at 2.5× FY2026E revenue.
THPlasma expands from 2 to 5 plasma collection centers across NJ and PA, projecting $32M revenue and $7M EBITDA in FY2026.
Combined entity leverages plasma-derived growth factor and exosome technologies from Carmell and Elevai to advance healthy aging therapeutics.
Why it matters:
This merger builds a vertically integrated plasma-to-therapeutics pipeline, strengthening biologics supply chains and accelerating commercial healthy aging treatments.
Q&A
What is an all-stock merger?
What are plasma-derived growth factors?
Why is the U.S. facing a plasma shortfall?
What is an earnout in M&A?
Read full article
Academy
Plasma Collection and Plasma-Derived Therapies in Longevity Science
Introduction: Blood plasma is the liquid component of blood that carries proteins, electrolytes, antibodies, and growth factors essential for laboratory analyses and therapeutic applications. Plasma collection centers perform controlled apheresis procedures to separate plasma from whole blood, returning blood cells to the donor. Plasma-derived products play a pivotal role in immunology, hemostasis, and regenerative medicine, making plasma supply a critical component of longevity science.
What Is Plasma? Plasma is a pale-yellow fluid comprising about 55% of total blood volume. It contains water, electrolytes like sodium and potassium, clotting factors such as fibrinogen, and immunoglobulins like IgG. Growth factors present in plasma, including platelet-derived growth factor and transforming growth factor-beta, regulate cell growth, migration, and repair processes. Understanding plasma composition helps researchers and clinicians harness its components for therapeutic development.
Plasma Collection Process: Donors undergo apheresis, during which blood is withdrawn and spun through a centrifuge or filtration system to extract plasma. The remaining cellular components—red cells, white cells, and platelets—are returned to the donor circulation. This procedure typically takes 60 to 90 minutes and can be repeated every few weeks, subject to regulatory guidelines. Safety measures include antibody screening, viral testing, and stringent donor eligibility criteria to ensure product purity.
Regulatory and Safety Considerations: In the United States, the Food and Drug Administration (FDA) regulates plasma collection centers and plasma-derived products under Title 21 CFR. Donor screening protocols assess health history, travel history, and risk factors. Plasma undergoes pathogen inactivation steps, including heat treatment or solvent-detergent processes, to reduce viral contamination risks. Traceability and batch testing are fundamental to meeting Good Manufacturing Practice (GMP) standards.
Plasma-Derived Therapies: Plasma-derived products include immunoglobulins used for immune deficiencies, clotting factors for hemophilia patients, and albumin for volume expansion in trauma care. Plasma-derived growth factors have emerging applications in dermatology, orthopedics, and regenerative bio-aesthetics. By isolating specific fractions, scientists can develop concentrated therapeutics that support tissue regeneration, modulate inflammation, and improve healing outcomes.
Role in Longevity Science: Longevity research explores how plasma-derived growth factors and immunomodulators can delay age-related decline. Therapeutic strategies include platelet-rich plasma (PRP) injections for tissue repair and wound healing. Plasma exosomes—nano-sized vesicles loaded with proteins and RNAs—are under investigation for their capacity to influence cellular communication, stem cell activation, and extracellular matrix remodeling in aging tissues.
Future Directions: Integrating plasma collection networks with biofactor extraction platforms offers a scalable pathway for next-generation therapeutics. Advances in apheresis technology, automation, and donor recruitment policies aim to expand plasma availability. Concurrently, high-throughput proteomics and exosome profiling drive personalized longevity interventions. Collaboration between biotech firms, clinical centers, and regulatory agencies will be key to translating plasma-derived discoveries into safe, effective longevity treatments.
- Apheresis Technology: Automated systems for efficient plasma separation and donor safety.
- Fractionation Methods: Chromatography and filtration techniques to isolate specific proteins and growth factors.
- Therapeutic Applications: Use of immunoglobulins, clotting factors, and growth factor concentrates in clinical care.
